219 related articles for article (PubMed ID: 18190706)
1. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
[TBL] [Abstract][Full Text] [Related]
2. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
[TBL] [Abstract][Full Text] [Related]
3. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.
Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
Mol Biol Cell; 2009 Jan; 20(1):319-27. PubMed ID: 18923142
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract][Full Text] [Related]
5. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
Donahue RN; McLaughlin PJ; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
[TBL] [Abstract][Full Text] [Related]
6. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
Zagon IS; McLaughlin PJ
Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
[TBL] [Abstract][Full Text] [Related]
7. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
8. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor.
McLaughlin PJ; Zagon IS
Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459
[TBL] [Abstract][Full Text] [Related]
9. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
10. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
Zagon IS; Porterfield NK; McLaughlin PJ
Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
[TBL] [Abstract][Full Text] [Related]
11. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
12. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Zagon IS; McLaughlin PJ
Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking.
Cheng F; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2010 Sep; 235(9):1093-101. PubMed ID: 20705629
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck.
McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS
Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790
[TBL] [Abstract][Full Text] [Related]
15. Expression of the tumor suppressor ARHI inhibits the growth of pancreatic cancer cells by inducing G1 cell cycle arrest.
Lu X; Qian J; Yu Y; Yang H; Li J
Oncol Rep; 2009 Sep; 22(3):635-40. PubMed ID: 19639215
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma.
Zagon IS; Smith JP; Conter R; McLaughlin PJ
Int J Mol Med; 2000 Jan; 5(1):77-84. PubMed ID: 10601579
[TBL] [Abstract][Full Text] [Related]
17. DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation.
Wang L; Cao XX; Chen Q; Zhu TF; Zhu HG; Zheng L
Cancer Sci; 2009 Oct; 100(10):1801-8. PubMed ID: 19572978
[TBL] [Abstract][Full Text] [Related]
18. Differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression.
Song JD; Kim KM; Kim KH; Kim CD; Kim JM; Yoo YH; Park YC
Int J Oncol; 2008 Dec; 33(6):1299-306. PubMed ID: 19020764
[TBL] [Abstract][Full Text] [Related]
19. Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation.
Li W; Hardwick MJ; Rosenthal D; Culty M; Papadopoulos V
Biochem Pharmacol; 2007 Feb; 73(4):491-503. PubMed ID: 17126818
[TBL] [Abstract][Full Text] [Related]
20. Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells.
Lee SH; Park C; Jin CY; Kim GY; Moon SK; Hyun JW; Lee WH; Choi BT; Kwon TK; Yoo YH; Choi YH
Biomed Pharmacother; 2008 Dec; 62(10):723-9. PubMed ID: 18222060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
